Version | 1.0 |
File Size | 16.40 mb |
File Count | 1 |
Create Date | July 13, 2022 |
Update Date | July 13, 2022 |
Telegram | Join Now |
Syllabus of Unit 2 :-
General Pharmacology
- Pharmacodynamics - Principles and mechanisms of drug action. Receptor theories and classification of receptors, regulation of receptors. drug receptors interactions signal transduction mechanisms, G-protein–coupled receptors, ion channel receptor, transmembrane enzyme linked receptors, transmembrane JAK-STAT binding receptor and receptors that regulate transcription factors, dose response relationship, therapeutic index, combined effects of drugs and factors modifying drug action.
- Adverse drug reactions.
- Drug interactions (pharmacokinetic and pharmacodynamics)
- Drug discovery and clinical evaluation of new drugs - Drug discovery phase, preclinical evaluation phase, clinical trial phase, phases of clinical trials and pharmacovigilance.
What is Pharmacodynamics ?
Pharmacodynamics is that the study of a drug's molecular, biochemical, and physiologic effects or actions. It comes from the Greek words "pharmakon," meaning "drug," and "dynamikos," meaning "power." All drugs produce their effects by interacting with biological structures or targets at the molecular level to induce a change in how the target molecule functions in respect to subsequent intermolecular interactions. These interactions include receptor binding, post-receptor effects, and chemical interactions.Samples of these sorts of interactions include:-
- Drugs binding to an energetic site of an enzyme
- Drugs that interact with cell surface signaling proteins to disrupt downstream signaling, and
- Drugs that act by binding molecules like tumor necrosis factor.
What is Adverse Drug Reactions ?
Since 2012, the definition has included reactions occurring as a results of error, misuse or abuse, and to suspected reactions to medicines that are unlicensed or being employed off-label additionally to the authorized use of a medicinal product in normal doses. While this transformation potentially alters the reporting and surveillance applied by manufactures and medicines regulators, in clinical practice it mustn't affect our approach to managing ADRs.
0 Comments
Post a Comment